Key result
BRD4 inhibition blocks pathological cardiac remodeling by suppressing stress-induced pathogenic transcription.
Why the study?
The specific roles of BRD4 in different cardiac cell types and its impact on pathological gene expression in heart failure require synthesis and clarification.
This review highlights the complex, cell type-specific epigenetic regulation by BRD4 in heart failure, suggesting that its targeted pharmacological inhibition could offer a promising therapeutic strategy against pathological cardiac remodeling.
Answers are grounded in this paper and cite their sources.
BRD4 inhibition may attenuate remodeling across cell types; leaves open clinical translation pending prospective trials.
PURPOSE OF REVIEW: This review synthesizes recent literature on cell type-specific roles for BRD4 in cardiac homeostasis and disease, emphasizing functions for this chromatin 'reader protein' in mediating pathologic gene signatures in heart failure. RECENT FINDINGS: Paradoxically, although knockout of BRD4 in cardiomyocytes is catastrophic, pharmacological inhibition of BRD4 blocks pathological cardiac remodeling via salutary effects in cardiomyocytes as well as in cardiac fibroblasts and macrophages. Mechanistically, dynamic targeting of BRD4 to gene enhancers and promoters governs stress-induced pathogenic transcriptional programs across myocyte and non-myocyte cell populations in the heart. Recent findings support roles for BRD4 in promoting pro-hypertrophic, pro-inflammatory, and pro-fibrotic gene expression via cell autonomous and non-autonomous actions in multiple cardiac cell types. Advancements in understanding the mechanisms by which BRD4 controls pathological gene expression in the heart should facilitate efforts to develop effective agents to target this epigenetic reader for the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Delaunay et al. (2026) conducted a review in Heart Failure. BRD4 pharmacological inhibition was evaluated on Pathological cardiac remodeling and gene expression. Pharmacological inhibition of BRD4 blocks pathological cardiac remodeling by governing stress-induced pathogenic transcriptional programs across multiple cardiac cell types.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: